Cargando…
Genome-wide association studies in pharmacogenomics: untapped potential for translation
Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to...
Autores principales: | , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684667/ https://www.ncbi.nlm.nih.gov/pubmed/19439031 http://dx.doi.org/10.1186/gm46 |
_version_ | 1782167255002382336 |
---|---|
author | Guessous, Idris Gwinn, Marta Khoury, Muin J |
author_facet | Guessous, Idris Gwinn, Marta Khoury, Muin J |
author_sort | Guessous, Idris |
collection | PubMed |
description | Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to yield clinical applications. Certain methodological concerns, such as selection bias and confounding, may be mitigated when genome-wide association studies are conducted within clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful definition of phenotype are incorporated by design. |
format | Text |
id | pubmed-2684667 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-26846672010-04-23 Genome-wide association studies in pharmacogenomics: untapped potential for translation Guessous, Idris Gwinn, Marta Khoury, Muin J Genome Med Commentary Despite large public investments in genome-wide association studies of common human diseases, so far, few gene discoveries have led to applications for clinical medicine or public health. Genome-wide association studies in the context of clinical trials of drug safety and efficacy may be quicker to yield clinical applications. Certain methodological concerns, such as selection bias and confounding, may be mitigated when genome-wide association studies are conducted within clinical trials, in which randomization of exposure, prospective evaluation of outcome and careful definition of phenotype are incorporated by design. BioMed Central 2009-04-28 /pmc/articles/PMC2684667/ /pubmed/19439031 http://dx.doi.org/10.1186/gm46 Text en Copyright ©2009 BioMed Central Ltd |
spellingShingle | Commentary Guessous, Idris Gwinn, Marta Khoury, Muin J Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title | Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title_full | Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title_fullStr | Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title_full_unstemmed | Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title_short | Genome-wide association studies in pharmacogenomics: untapped potential for translation |
title_sort | genome-wide association studies in pharmacogenomics: untapped potential for translation |
topic | Commentary |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2684667/ https://www.ncbi.nlm.nih.gov/pubmed/19439031 http://dx.doi.org/10.1186/gm46 |
work_keys_str_mv | AT guessousidris genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation AT gwinnmarta genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation AT khourymuinj genomewideassociationstudiesinpharmacogenomicsuntappedpotentialfortranslation |